Affimed (AFMD) Stock Forecast & Price Target

$5.12

+0.02 (+0.39%)

(As of 07/26/2024 ET)

Affimed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Affimed in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for AFMD.

Consensus Price Target

$41.67
713.80% Upside

High Forecast	$70.00
Average Forecast	$41.67
Low Forecast	$10.00

According to the 6 analysts' twelve-month price targets for Affimed, the average price target is $41.67. The highest price target for AFMD is $70.00, while the lowest price target for AFMD is $10.00. The average price target represents a forecasted upside of 713.80% from the current price of $5.12.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$41.67	$41.67	$45.00	$55.00
Forecasted Upside	713.80% Upside	599.64% Upside	740.42% Upside	336.43% Upside

Get Affimed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

AFMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AFMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Affimed Stock vs. The Competition

Type	Affimed	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	713.80% Upside	3,123.46% Upside	9.10% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/13/2024	Laidlaw 5 of 5 stars	Boost Target	Buy	$15.00 ➝ $25.00	+252.11%
6/13/2024	HC Wainwright 3 of 5 stars	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+45.77%
4/1/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight
4/1/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$30.00 ➝ $25.00	+357.87%
8/11/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$80.00 ➝ $60.00	+1,003.95%
8/8/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$60.00	+971.43%
3/24/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold	$20.00 ➝ $10.00	+42.51%
12/12/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$100.00 ➝ $60.00	+194.12%
12/12/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$70.00 ➝ $60.00	+194.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:16 AM ET.

AFMD Forecast - Frequently Asked Questions

What is Affimed's forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Affimed is $41.67, with a high forecast of $70.00 and a low forecast of $10.00.
Should I buy or sell Affimed stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
Does Affimed's stock price have much upside?: According to analysts, Affimed's stock has a predicted upside of 599.64% based on their 12-month stock forecasts.
What analysts cover Affimed?: Affimed has been rated by research analysts at HC Wainwright, and Laidlaw in the past 90 days.
Do Wall Street analysts like Affimed more than its competitors?: Analysts like Affimed more than other "medical" companies. The consensus rating for Affimed is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AFMD compares to other companies.